Trials / Recruiting
RecruitingNCT06037473
The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg
A Real-world Study of the Efficacy and Safety of PEGylated Recombinant Human Growth Hormone Injection in the Treatment of Short Stature in Chinese Children From the Global Registry for Novel Therapies For Rare Bone or Endocrine Conditions
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,600 (estimated)
- Sponsor
- Beijing Children's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In order to further observe the long-term safety and effectiveness of real-world polyethylene glycol-recombinant human growth hormone(PEG-rhGH) treatment of GHD, idiopathic short stature, and SGA in children, explore and analyze the factors affecting the efficacy of PEG-rhGH and the height prediction model after treatment, etc., collect and analyze more scientifically and rationally, and understand the situation of real-world PEG-GH treatment. A database registration study was developed.
Detailed description
A database registration study was developed to retrospectively analyze the efficacy and safety of polyethylene glycol recombinant human growth hormone injection in the treatment of slow growth in children caused by endogenous growth hormone deficiency, idiopathic short stature, Turner syndrome, etc., and to further prospectively follow up and monitor. In order to participate in the global real-world use of long-acting growth hormone, all data from this study were uploaded to the Global Registry of New Therapies for Rare Endocrine Diseases and Bone Disorders (GloBE-Reg) platform.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Polyethylene glycol recombinant human growth hormone injection | 0.1-0.3mg/kg.w |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2029-01-01
- Completion
- 2029-08-01
- First posted
- 2023-09-14
- Last updated
- 2025-09-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06037473. Inclusion in this directory is not an endorsement.